At a glance
ClinicalIndex Comparison RecordN/ACompleted· 2,654 enrolled
Drug / intervention
Extra-fine hydrofluoroalkane beclometasone dipropionate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparative Effectiveness of Extrafine Hydrofluoroalkane Beclometasone Versus Fluticasone in Paediatric Patients - a Retrospective, Real-life Observational Study in a uk Primary Care Asthma Population
In Brief
An observational study evaluating Extra-fine hydrofluoroalkane beclometasone dipropionate and Fluticasone propionate for Asthma. Completed, enrolled 2,654 participants.
Detailed Summary
The primary aim of this study was to compare the absolute and relative effectiveness of asthma management in paediatric patients in the UK on inhaled corticosteroid (ICS) maintenance therapy as extra-fine HFA-BDP (Qvar®) pressurised metered dose inhaler (pMDI) compared with fluticasone propionate (FP) pMDI.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
Countries--
CollaboratorsTeva Branded Pharmaceutical Products R&D, Inc.
Timeline
N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2011
Primary CompletionMar 2013
First PostedJun 2013
TodayJul 2026
First PostedJun 14, 2013
Enrollment StartFeb 1, 2011
Primary CompletionMar 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 13.0 years ago
Interventions
Extra-fine hydrofluoroalkane beclometasone dipropionatedrug
Fluticasone propionatedrug